Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: Synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS

Analytical and Bioanalytical Chemistry

Volumn 407, Issue 6, 2015, Pages 1545-1557

  Wink, Carina S D ^a   Meyer, Golo M J ^a   Zapp, Josef ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Drugs of abuse; GC MS; LC HR MS MS; Lefetamine; Metabolism

Indexed keywords

ALKYLATION; BIOMOLECULES; BODY FLUIDS; DRUG PRODUCTS; GAS CHROMATOGRAPHY; HYDROXYLATION; INDIUM COMPOUNDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES; ORGANIC POLYMERS; PHYSIOLOGY;

DRUGS OF ABUSE; GAS CHROMATOGRAPHY-MASS SPECTROMETRIES (GC-MS); GC-MS; HYDROXY METABOLITES; LC-HR-MS/MS; LEFETAMINE; LIQUID CHROMATOGRAPHY HIGH RESOLUTION TANDEM MASS SPECTROMETRIES; SCREENING APPROACHES;

CONTROLLED DRUG DELIVERY;

RATTUS;

LEFETAMINE; PHENETHYLAMINE DERIVATIVE;

ANIMAL; CARBON NUCLEAR MAGNETIC RESONANCE; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SYNTHESIS; TANDEM MASS SPECTROMETRY; URINE; WISTAR RAT;

ANIMALS; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; CHROMATOGRAPHY, LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIMIT OF DETECTION; LIVER; MALE; PHENETHYLAMINES; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84925542866     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-8414-3     Document Type: Article

References (21)

1. Expert Committee on Addiction-Producing Drugs (1961) Expert committee on addiction-producing drugs. Eleventh report. World Health Organ Tech Rep Ser 211:1-16
2. Paroli E, Nencini P, Moscucci M (1984) Clinical and experimental evidence of an opiate-like activity of lefetamine. Pharmacol Res Commun 16:915-922
3. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E (1994) Opiate detoxification of methadone maintenance patients using lefetamine, clonidine, and buprenorphine. Drug Alcohol Depend 36:139-145
4. Mannelli P, Janiri L, De MM, Tempesta E (1989) Lefetamine: new abuse of an old drug - clinical evaluation of opioid activity. Drug Alcohol Depend 24:95-101
5. De Montis MG, Devoto P, Bucarelli A, Tagliamonte A (1985) Opioid activity of lefetamine. Pharmacol Res Commun 17:471-478
6. Janiri L, Persico AM, Tempesta E (1989) Dual effects of lephetamine on spontaneous and evoked neuronal firing in the somatosensory cortex of the rat. Neuropharmacology 28:1405-1410
7. Westphal F, Junge T, Jacobsen-Bauer A, Rösner P (2010) Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech 77:46-58
8. n and LC-high resolution (HR)-MS/MS. Drug Test Anal 6:1038-1048
9. Maurer HH, Pfleger K, Weber AA (2011) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, Weinheim
10. n screening concept. Anal Bioanal Chem 400:3481-3489
11. n library of drugs, poisons, and their metabolites. Wiley-VCH, Weinheim
12. Rosenau T, Potthast A, Rohrling J, Hofinger A, Sixta H, Kosma P (2002) A solvent-free and formalin-free Eschweiler-Clarke methylation for amines. Synth Commun 32:457-466
13. Moore JL, Taylor SM, Soloshonok VA (2005) An efficient and operationally convenient general synthesis of tertiary amines by direct alkylation of secondary amines with alkyl halides in the presence of Huenig's base. Arkivoc (Arch Organ Chem) 2005:287-292
14. Malz F (2003) Quantitative NMR-Specktroskopie als Referenzverfahren in der alaytischen Chemie. PhD thesis, Humboldt-Universita¨t Berlin, Berlin
15. n, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high "Kanna" isolated from Sceletium tortuosum. Anal Bioanal Chem. doi: 10.1007/s00216-014-8109-9
16. Maurer HH, Pfleger K, Weber AA (2011) Mass spectral library of drugs, poisons, pesticides, pollutants, and their metabolites. Wiley-VCH, Weinheim
17. Meyer MR, Peters FT, Maurer HH (2010) Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin Chem 56:575-584
18. n urine drug screening procedure - exemplified for antidepressants. Anal Bioanal Chem 400:79-88
19. McLafferty FW, Turecek F (1993) Interpretation of mass spectra. University Science Books, Mill Valley
20. Smith RM, Busch KL (1999) Understanding mass spectra - a basic approach. Wiley, New York
21. Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907-921